Back to Research Hub
Praxis Precision Medicines, Inc.
PRAX
$250.33-2.92 (-1.15%)
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.
StreetsValue research for Praxis Precision Medicines, Inc. (PRAX)
Members get the full report for Praxis Precision Medicines, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.